Share Price and Basic Stock Data
Last Updated: January 29, 2026, 10:55 am
| PEG Ratio | 0.04 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Nath Bio-Genes (India) Ltd operates in the seeds, tissue culture, and biotechnology sectors, with a share price of ₹141 and a market capitalization of ₹263 Cr. The company’s revenue has shown a significant upward trajectory, with reported sales for the financial year ending in March 2025 standing at ₹265 Cr, compared to ₹234 Cr in March 2023. This growth reflects a compound annual growth rate (CAGR) of approximately 6.64% over two years. Quarterly sales also illustrate this positive trend, with the June 2024 quarter recording sales of ₹243.88 Cr, indicating strong seasonal performance. However, the most recent quarter ending September 2023 reported sales of ₹22.57 Cr, highlighting volatility in revenue generation. The company’s operational efficiency is evident in its ability to maintain a consistent operating profit margin (OPM) of 18.08%, which aligns with industry averages, suggesting effective cost management despite fluctuating sales figures.
Profitability and Efficiency Metrics
Nath Bio-Genes reported a net profit of ₹50 Cr for the financial year ending March 2025, a notable recovery from a loss of ₹67 Cr in March 2022. The net profit margin has stabilized at 10.57%, reflecting improved profitability compared to the previous year’s margin of 11.91%. The return on equity (ROE) stood at 6.77%, indicating a reasonable return on shareholders’ investments, while the return on capital employed (ROCE) was recorded at 7.35%. The interest coverage ratio (ICR) of 5.18x suggests that the company can comfortably meet its interest obligations, which is critical given its borrowings of ₹142 Cr. The company’s cash conversion cycle (CCC) of 122 days indicates a relatively efficient management of working capital, although it slightly exceeds the industry average. Overall, the profitability metrics demonstrate resilience, but the declining trend in margins and fluctuating quarterly profits raise concerns about long-term sustainability.
Balance Sheet Strength and Financial Ratios
Nath Bio-Genes maintains a robust balance sheet, with total reserves recorded at ₹668 Cr versus borrowings of ₹142 Cr, indicating a healthy reserves-to-borrowings ratio. The company’s total assets stood at ₹1,005 Cr, reflecting a steady increase from ₹793 Cr in March 2023. The price-to-book value (P/BV) ratio is notably low at 0.43x, suggesting that the market may undervalue the company’s assets relative to its book value. The current ratio of 1.89x indicates adequate short-term liquidity, while the debt-to-equity ratio of 0.19x demonstrates a conservative approach to leveraging. Additionally, the company’s operating profit margin (OPM) remains stable at 18.08%, which is commendable amid rising operational costs. The efficiency ratios, including an asset turnover ratio of 0.38%, indicate that the firm is generating revenue efficiently relative to its asset base, although there is room for improvement in optimizing asset utilization.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Nath Bio-Genes reveals a significant level of promoter ownership at 45.59%, which is stable over recent quarters. This level of insider ownership typically instills confidence among retail investors. Institutional holdings are relatively low, with foreign institutional investors (FIIs) at 0.32% and domestic institutional investors (DIIs) at 0.76%. Public shareholding has increased to 53.31%, indicating growing interest from retail investors. The total number of shareholders has slightly declined from 34,749 in December 2022 to 34,122 in September 2025, suggesting a potential consolidation of investor confidence. The low institutional ownership could be a cause for concern, as it may limit the company’s visibility among larger investment funds. Nevertheless, the stability in promoter holdings indicates confidence in the company’s future prospects and strategic direction.
Outlook, Risks, and Final Insight
Looking ahead, Nath Bio-Genes is positioned for moderate growth, driven by its established market presence in the seeds and biotechnology sectors. However, the company faces several risks, including fluctuating sales and profitability margins, which could impact overall financial stability. Additionally, with a cash conversion cycle of 122 days, there is potential for liquidity challenges if operational efficiencies do not improve. On the upside, the company’s strong balance sheet, evidenced by low debt levels and substantial reserves, provides a buffer against economic downturns. If Nath Bio-Genes can enhance its operational efficiency and stabilize its revenue streams, it could leverage its current market position for sustained growth. Conversely, failure to address the volatility in sales and maintain profitability could hinder its ability to attract institutional investors and achieve long-term strategic goals.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Genomic Valley Biotech Ltd | 7.09 Cr. | 23.2 | 70.9/20.1 | 12.8 | 0.00 % | 11.8 % | 9.69 % | 10.0 | |
| Genesis IBRC India Ltd | 112 Cr. | 86.2 | 185/18.3 | 6.42 | 0.00 % | 51.6 % | 51.6 % | 10.0 | |
| Shreeoswal Seeds & Chemicals Ltd | 124 Cr. | 13.5 | 20.3/10.7 | 12.4 | 5.23 | 0.00 % | 9.88 % | 8.41 % | 2.00 |
| Nath Bio-Genes (India) Ltd | 270 Cr. | 142 | 239/136 | 5.73 | 362 | 1.41 % | 7.35 % | 6.77 % | 10.0 |
| Continental Seeds and Chemicals Ltd | 28.8 Cr. | 21.0 | 34.8/19.3 | 37.4 | 22.5 | 0.00 % | 4.24 % | 2.87 % | 10.0 |
| Industry Average | 168.67 Cr | 57.18 | 18.51 | 81.79 | 0.28% | 16.97% | 15.87% | 8.40 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 21.73 | 25.30 | 44.92 | 235.28 | 22.57 | 31.74 | 43.04 | 243.88 | 32.19 | 36.87 | 49.37 | 280.17 | 39.77 |
| Expenses | 16.98 | 19.68 | 40.84 | 198.26 | 17.48 | 25.96 | 38.57 | 206.82 | 25.63 | 29.36 | 46.20 | 241.27 | 32.58 |
| Operating Profit | 4.75 | 5.62 | 4.08 | 37.02 | 5.09 | 5.78 | 4.47 | 37.06 | 6.56 | 7.51 | 3.17 | 38.90 | 7.19 |
| OPM % | 21.86% | 22.21% | 9.08% | 15.73% | 22.55% | 18.21% | 10.39% | 15.20% | 20.38% | 20.37% | 6.42% | 13.88% | 18.08% |
| Other Income | 0.20 | 0.06 | 0.26 | 0.12 | 0.06 | 2.54 | 1.39 | 0.14 | 0.07 | 0.48 | 4.58 | 3.83 | 1.93 |
| Interest | 2.75 | 2.96 | 1.53 | 2.76 | 2.44 | 2.84 | 1.06 | 2.24 | 2.94 | 3.37 | 1.10 | 2.89 | 3.30 |
| Depreciation | 0.67 | 0.67 | 0.99 | 0.76 | 0.76 | 0.76 | 0.98 | 0.83 | 0.83 | 0.83 | 1.32 | 0.98 | 0.98 |
| Profit before tax | 1.53 | 2.05 | 1.82 | 33.62 | 1.95 | 4.72 | 3.82 | 34.13 | 2.86 | 3.79 | 5.33 | 38.86 | 4.84 |
| Tax % | 3.92% | 34.15% | 12.64% | 0.65% | 17.95% | 16.31% | 16.23% | 0.73% | -1.05% | 30.08% | 11.82% | 1.70% | 13.22% |
| Net Profit | 1.47 | 1.35 | 1.59 | 33.40 | 1.61 | 3.96 | 3.21 | 33.89 | 2.89 | 2.66 | 4.71 | 38.21 | 4.20 |
| EPS in Rs | 0.77 | 0.71 | 0.84 | 17.58 | 0.85 | 2.08 | 1.69 | 17.83 | 1.52 | 1.40 | 2.48 | 20.11 | 2.21 |
Last Updated: January 11, 2026, 7:47 am
Below is a detailed analysis of the quarterly data for Nath Bio-Genes (India) Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 39.77 Cr.. The value appears to be declining and may need further review. It has decreased from 280.17 Cr. (Jun 2025) to 39.77 Cr., marking a decrease of 240.40 Cr..
- For Expenses, as of Sep 2025, the value is 32.58 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 241.27 Cr. (Jun 2025) to 32.58 Cr., marking a decrease of 208.69 Cr..
- For Operating Profit, as of Sep 2025, the value is 7.19 Cr.. The value appears to be declining and may need further review. It has decreased from 38.90 Cr. (Jun 2025) to 7.19 Cr., marking a decrease of 31.71 Cr..
- For OPM %, as of Sep 2025, the value is 18.08%. The value appears strong and on an upward trend. It has increased from 13.88% (Jun 2025) to 18.08%, marking an increase of 4.20%.
- For Other Income, as of Sep 2025, the value is 1.93 Cr.. The value appears to be declining and may need further review. It has decreased from 3.83 Cr. (Jun 2025) to 1.93 Cr., marking a decrease of 1.90 Cr..
- For Interest, as of Sep 2025, the value is 3.30 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2.89 Cr. (Jun 2025) to 3.30 Cr., marking an increase of 0.41 Cr..
- For Depreciation, as of Sep 2025, the value is 0.98 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.98 Cr..
- For Profit before tax, as of Sep 2025, the value is 4.84 Cr.. The value appears to be declining and may need further review. It has decreased from 38.86 Cr. (Jun 2025) to 4.84 Cr., marking a decrease of 34.02 Cr..
- For Tax %, as of Sep 2025, the value is 13.22%. The value appears to be increasing, which may not be favorable. It has increased from 1.70% (Jun 2025) to 13.22%, marking an increase of 11.52%.
- For Net Profit, as of Sep 2025, the value is 4.20 Cr.. The value appears to be declining and may need further review. It has decreased from 38.21 Cr. (Jun 2025) to 4.20 Cr., marking a decrease of 34.01 Cr..
- For EPS in Rs, as of Sep 2025, the value is 2.21. The value appears to be declining and may need further review. It has decreased from 20.11 (Jun 2025) to 2.21, marking a decrease of 17.90.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:55 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 136 | 143 | 127 | 142 | 171 | 206 | 246 | 271 | 230 | 234 | 248 | 265 | 406 |
| Expenses | 102 | 109 | 103 | 113 | 131 | 163 | 191 | 204 | 193 | 185 | 197 | 212 | 349 |
| Operating Profit | 34 | 35 | 25 | 29 | 40 | 43 | 55 | 67 | 37 | 49 | 50 | 53 | 57 |
| OPM % | 25% | 24% | 19% | 20% | 24% | 21% | 22% | 25% | 16% | 21% | 20% | 20% | 14% |
| Other Income | 1 | 1 | 1 | 0 | 1 | 2 | 2 | 2 | -87 | 1 | 4 | 4 | 11 |
| Interest | 4 | 5 | 6 | 10 | 10 | 5 | 7 | 9 | 11 | 10 | 9 | 10 | 11 |
| Depreciation | 5 | 4 | 4 | 3 | 1 | 1 | 1 | 3 | 3 | 3 | 3 | 4 | 4 |
| Profit before tax | 26 | 26 | 15 | 17 | 30 | 39 | 49 | 57 | -63 | 36 | 42 | 44 | 53 |
| Tax % | 5% | 4% | 6% | 3% | 2% | 1% | -4% | 2% | 6% | 3% | 5% | 4% | |
| Net Profit | 24 | 25 | 14 | 16 | 29 | 38 | 50 | 56 | -67 | 35 | 40 | 42 | 50 |
| EPS in Rs | 15.18 | 15.87 | 8.85 | 10.17 | 15.48 | 20.22 | 26.56 | 29.29 | -35.43 | 18.51 | 21.14 | 22.17 | 26.20 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 7% | -6% | 11% | 9% | 9% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 4.17% | -44.00% | 14.29% | 81.25% | 31.03% | 31.58% | 12.00% | -219.64% | 152.24% | 14.29% | 5.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | -48.17% | 58.29% | 66.96% | -50.22% | 0.54% | -19.58% | -231.64% | 371.88% | -137.95% | -9.29% |
Nath Bio-Genes (India) Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 2% |
| 3 Years: | 5% |
| TTM: | 17% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | -3% |
| 3 Years: | 21% |
| TTM: | 17% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | -10% |
| 3 Years: | -1% |
| 1 Year: | -22% |
| Return on Equity | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 7% |
| 3 Years: | 6% |
| Last Year: | 7% |
Last Updated: September 5, 2025, 11:35 am
Balance Sheet
Last Updated: December 4, 2025, 1:42 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 16 | 16 | 16 | 16 | 19 | 19 | 19 | 19 | 19 | 19 | 19 | 19 | 19 |
| Reserves | 66 | 91 | 105 | 287 | 450 | 489 | 539 | 594 | 523 | 554 | 592 | 630 | 668 |
| Borrowings | 23 | 22 | 59 | 74 | 33 | 58 | 70 | 101 | 93 | 105 | 108 | 111 | 142 |
| Other Liabilities | 85 | 97 | 87 | 78 | 69 | 80 | 102 | 75 | 105 | 114 | 158 | 257 | 176 |
| Total Liabilities | 190 | 226 | 267 | 455 | 571 | 646 | 730 | 790 | 740 | 793 | 877 | 1,017 | 1,005 |
| Fixed Assets | 17 | 13 | 30 | 207 | 211 | 232 | 246 | 247 | 245 | 244 | 249 | 250 | 249 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 6 | 6 | 6 |
| Other Assets | 168 | 208 | 231 | 243 | 355 | 409 | 479 | 538 | 490 | 544 | 622 | 761 | 750 |
| Total Assets | 190 | 226 | 267 | 455 | 571 | 646 | 730 | 790 | 740 | 793 | 877 | 1,017 | 1,005 |
Below is a detailed analysis of the balance sheet data for Nath Bio-Genes (India) Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 19.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 19.00 Cr..
- For Reserves, as of Sep 2025, the value is 668.00 Cr.. The value appears strong and on an upward trend. It has increased from 630.00 Cr. (Mar 2025) to 668.00 Cr., marking an increase of 38.00 Cr..
- For Borrowings, as of Sep 2025, the value is 142.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 111.00 Cr. (Mar 2025) to 142.00 Cr., marking an increase of 31.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 176.00 Cr.. The value appears to be improving (decreasing). It has decreased from 257.00 Cr. (Mar 2025) to 176.00 Cr., marking a decrease of 81.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 1,005.00 Cr.. The value appears to be improving (decreasing). It has decreased from 1,017.00 Cr. (Mar 2025) to 1,005.00 Cr., marking a decrease of 12.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 249.00 Cr.. The value appears to be declining and may need further review. It has decreased from 250.00 Cr. (Mar 2025) to 249.00 Cr., marking a decrease of 1.00 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 6.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 6.00 Cr..
- For Other Assets, as of Sep 2025, the value is 750.00 Cr.. The value appears to be declining and may need further review. It has decreased from 761.00 Cr. (Mar 2025) to 750.00 Cr., marking a decrease of 11.00 Cr..
- For Total Assets, as of Sep 2025, the value is 1,005.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,017.00 Cr. (Mar 2025) to 1,005.00 Cr., marking a decrease of 12.00 Cr..
Notably, the Reserves (668.00 Cr.) exceed the Borrowings (142.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 11.00 | 13.00 | -34.00 | -45.00 | 7.00 | -15.00 | -15.00 | -34.00 | -56.00 | -56.00 | -58.00 | -58.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 95 | 114 | 130 | 133 | 175 | 191 | 159 | 147 | 136 | 152 | 139 | 122 |
| Inventory Days | 3,840 | 4,743 | 4,388 | |||||||||
| Days Payable | 1,309 | 1,406 | 586 | |||||||||
| Cash Conversion Cycle | 95 | 114 | 130 | 2,665 | 3,512 | 191 | 159 | 147 | 136 | 3,954 | 139 | 122 |
| Working Capital Days | 126 | 190 | 259 | 273 | 447 | 442 | 416 | 450 | 427 | 416 | 343 | 316 |
| ROCE % | 33% | 26% | 14% | 10% | 9% | 8% | 9% | 10% | 5% | 7% | 7% | 7% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Aditya Birla Sun Life Value Fund | 126,341 | 0.03 | 2.08 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 13 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 19.85 | 19.52 | 18.43 | -35.55 | 7.34 |
| Diluted EPS (Rs.) | 19.85 | 19.52 | 18.43 | -35.55 | 7.34 |
| Cash EPS (Rs.) | 22.32 | 22.56 | 20.01 | -33.84 | 10.16 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 339.08 | 320.94 | 301.60 | 285.16 | 35.91 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 339.08 | 320.94 | 301.60 | 285.16 | 35.91 |
| Revenue From Operations / Share (Rs.) | 192.02 | 175.03 | 158.58 | 146.47 | 86.04 |
| PBDIT / Share (Rs.) | 28.60 | 26.57 | 25.94 | 20.54 | 12.80 |
| PBIT / Share (Rs.) | 26.59 | 24.85 | 24.36 | 18.92 | 9.98 |
| PBT / Share (Rs.) | 21.36 | 21.87 | 19.03 | -33.38 | 7.68 |
| Net Profit / Share (Rs.) | 20.31 | 20.85 | 18.42 | -35.46 | 7.34 |
| NP After MI And SOA / Share (Rs.) | 20.31 | 20.85 | 18.42 | -35.46 | 7.34 |
| PBDIT Margin (%) | 14.89 | 15.17 | 16.35 | 14.02 | 14.87 |
| PBIT Margin (%) | 13.84 | 14.19 | 15.35 | 12.91 | 11.59 |
| PBT Margin (%) | 11.12 | 12.49 | 12.00 | -22.78 | 8.92 |
| Net Profit Margin (%) | 10.57 | 11.91 | 11.61 | -24.20 | 8.52 |
| NP After MI And SOA Margin (%) | 10.57 | 11.91 | 11.61 | -24.20 | 8.52 |
| Return on Networth / Equity (%) | 5.99 | 6.49 | 6.10 | -12.43 | 20.43 |
| Return on Capital Employeed (%) | 7.64 | 7.64 | 8.03 | 6.59 | 26.54 |
| Return On Assets (%) | 3.76 | 4.50 | 4.41 | -9.11 | 7.42 |
| Long Term Debt / Equity (X) | 0.02 | 0.01 | 0.00 | 0.00 | 0.02 |
| Total Debt / Equity (X) | 0.19 | 0.18 | 0.18 | 0.17 | 0.31 |
| Asset Turnover Ratio (%) | 0.38 | 0.39 | 0.39 | 0.00 | 1.05 |
| Current Ratio (X) | 1.89 | 2.18 | 2.41 | 2.41 | 1.22 |
| Quick Ratio (X) | 0.96 | 1.30 | 1.45 | 1.27 | 0.43 |
| Inventory Turnover Ratio (X) | 1.28 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend Payout Ratio (NP) (%) | 9.84 | 9.59 | 10.85 | -5.64 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 8.96 | 8.86 | 9.99 | -5.91 | 0.00 |
| Earning Retention Ratio (%) | 90.16 | 90.41 | 89.15 | 105.64 | 0.00 |
| Cash Earning Retention Ratio (%) | 91.04 | 91.14 | 90.01 | 105.91 | 0.00 |
| Interest Coverage Ratio (X) | 5.18 | 5.54 | 4.87 | 3.68 | 5.58 |
| Interest Coverage Ratio (Post Tax) (X) | 4.63 | 4.97 | 4.46 | 3.02 | 4.20 |
| Enterprise Value (Cr.) | 310.77 | 363.13 | 336.48 | 494.22 | 0.00 |
| EV / Net Operating Revenue (X) | 0.85 | 1.09 | 1.12 | 1.78 | 0.00 |
| EV / EBITDA (X) | 5.72 | 7.19 | 6.83 | 12.66 | 0.00 |
| MarketCap / Net Operating Revenue (X) | 0.75 | 0.99 | 0.89 | 1.46 | 0.00 |
| Retention Ratios (%) | 90.15 | 90.40 | 89.14 | 105.64 | 0.00 |
| Price / BV (X) | 0.43 | 0.54 | 0.46 | 0.74 | 0.00 |
| Price / Net Operating Revenue (X) | 0.75 | 0.99 | 0.89 | 1.46 | 0.00 |
| EarningsYield | 0.13 | 0.11 | 0.13 | -0.16 | 0.00 |
After reviewing the key financial ratios for Nath Bio-Genes (India) Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 19.85. This value is within the healthy range. It has increased from 19.52 (Mar 24) to 19.85, marking an increase of 0.33.
- For Diluted EPS (Rs.), as of Mar 25, the value is 19.85. This value is within the healthy range. It has increased from 19.52 (Mar 24) to 19.85, marking an increase of 0.33.
- For Cash EPS (Rs.), as of Mar 25, the value is 22.32. This value is within the healthy range. It has decreased from 22.56 (Mar 24) to 22.32, marking a decrease of 0.24.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 339.08. It has increased from 320.94 (Mar 24) to 339.08, marking an increase of 18.14.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 339.08. It has increased from 320.94 (Mar 24) to 339.08, marking an increase of 18.14.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 192.02. It has increased from 175.03 (Mar 24) to 192.02, marking an increase of 16.99.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 28.60. This value is within the healthy range. It has increased from 26.57 (Mar 24) to 28.60, marking an increase of 2.03.
- For PBIT / Share (Rs.), as of Mar 25, the value is 26.59. This value is within the healthy range. It has increased from 24.85 (Mar 24) to 26.59, marking an increase of 1.74.
- For PBT / Share (Rs.), as of Mar 25, the value is 21.36. This value is within the healthy range. It has decreased from 21.87 (Mar 24) to 21.36, marking a decrease of 0.51.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 20.31. This value is within the healthy range. It has decreased from 20.85 (Mar 24) to 20.31, marking a decrease of 0.54.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 20.31. This value is within the healthy range. It has decreased from 20.85 (Mar 24) to 20.31, marking a decrease of 0.54.
- For PBDIT Margin (%), as of Mar 25, the value is 14.89. This value is within the healthy range. It has decreased from 15.17 (Mar 24) to 14.89, marking a decrease of 0.28.
- For PBIT Margin (%), as of Mar 25, the value is 13.84. This value is within the healthy range. It has decreased from 14.19 (Mar 24) to 13.84, marking a decrease of 0.35.
- For PBT Margin (%), as of Mar 25, the value is 11.12. This value is within the healthy range. It has decreased from 12.49 (Mar 24) to 11.12, marking a decrease of 1.37.
- For Net Profit Margin (%), as of Mar 25, the value is 10.57. This value exceeds the healthy maximum of 10. It has decreased from 11.91 (Mar 24) to 10.57, marking a decrease of 1.34.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 10.57. This value is within the healthy range. It has decreased from 11.91 (Mar 24) to 10.57, marking a decrease of 1.34.
- For Return on Networth / Equity (%), as of Mar 25, the value is 5.99. This value is below the healthy minimum of 15. It has decreased from 6.49 (Mar 24) to 5.99, marking a decrease of 0.50.
- For Return on Capital Employeed (%), as of Mar 25, the value is 7.64. This value is below the healthy minimum of 10. There is no change compared to the previous period (Mar 24) which recorded 7.64.
- For Return On Assets (%), as of Mar 25, the value is 3.76. This value is below the healthy minimum of 5. It has decreased from 4.50 (Mar 24) to 3.76, marking a decrease of 0.74.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.02. This value is below the healthy minimum of 0.2. It has increased from 0.01 (Mar 24) to 0.02, marking an increase of 0.01.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.19. This value is within the healthy range. It has increased from 0.18 (Mar 24) to 0.19, marking an increase of 0.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.38. It has decreased from 0.39 (Mar 24) to 0.38, marking a decrease of 0.01.
- For Current Ratio (X), as of Mar 25, the value is 1.89. This value is within the healthy range. It has decreased from 2.18 (Mar 24) to 1.89, marking a decrease of 0.29.
- For Quick Ratio (X), as of Mar 25, the value is 0.96. This value is below the healthy minimum of 1. It has decreased from 1.30 (Mar 24) to 0.96, marking a decrease of 0.34.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.28. This value is below the healthy minimum of 4. It has increased from 0.00 (Mar 24) to 1.28, marking an increase of 1.28.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 9.84. This value is below the healthy minimum of 20. It has increased from 9.59 (Mar 24) to 9.84, marking an increase of 0.25.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 8.96. This value is below the healthy minimum of 20. It has increased from 8.86 (Mar 24) to 8.96, marking an increase of 0.10.
- For Earning Retention Ratio (%), as of Mar 25, the value is 90.16. This value exceeds the healthy maximum of 70. It has decreased from 90.41 (Mar 24) to 90.16, marking a decrease of 0.25.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 91.04. This value exceeds the healthy maximum of 70. It has decreased from 91.14 (Mar 24) to 91.04, marking a decrease of 0.10.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 5.18. This value is within the healthy range. It has decreased from 5.54 (Mar 24) to 5.18, marking a decrease of 0.36.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 4.63. This value is within the healthy range. It has decreased from 4.97 (Mar 24) to 4.63, marking a decrease of 0.34.
- For Enterprise Value (Cr.), as of Mar 25, the value is 310.77. It has decreased from 363.13 (Mar 24) to 310.77, marking a decrease of 52.36.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.85. This value is below the healthy minimum of 1. It has decreased from 1.09 (Mar 24) to 0.85, marking a decrease of 0.24.
- For EV / EBITDA (X), as of Mar 25, the value is 5.72. This value is within the healthy range. It has decreased from 7.19 (Mar 24) to 5.72, marking a decrease of 1.47.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.75. This value is below the healthy minimum of 1. It has decreased from 0.99 (Mar 24) to 0.75, marking a decrease of 0.24.
- For Retention Ratios (%), as of Mar 25, the value is 90.15. This value exceeds the healthy maximum of 70. It has decreased from 90.40 (Mar 24) to 90.15, marking a decrease of 0.25.
- For Price / BV (X), as of Mar 25, the value is 0.43. This value is below the healthy minimum of 1. It has decreased from 0.54 (Mar 24) to 0.43, marking a decrease of 0.11.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.75. This value is below the healthy minimum of 1. It has decreased from 0.99 (Mar 24) to 0.75, marking a decrease of 0.24.
- For EarningsYield, as of Mar 25, the value is 0.13. This value is below the healthy minimum of 5. It has increased from 0.11 (Mar 24) to 0.13, marking an increase of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Nath Bio-Genes (India) Ltd:
- Net Profit Margin: 10.57%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 7.64% (Industry Average ROCE: 16.97%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 5.99% (Industry Average ROE: 15.87%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 4.63
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.96
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 5.73 (Industry average Stock P/E: 18.51)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.19
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 10.57%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Seeds/Tissue Culture/Bio Technology | Nath House, Aurangabad Maharashtra 431005 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Satish Kagliwal | Managing Director |
| Mr. Madhukar Deshpande | Director |
| Ms. Ashu Jain | Director |
| Mrs. Jeevanlata Kagliwal | Director |
| Mr. Vadla Nagabhushanam | Director |
| Mr. Hitesh Purohit | Director |
| Mr. Akash Kagliwal | Director |
FAQ
What is the intrinsic value of Nath Bio-Genes (India) Ltd?
Nath Bio-Genes (India) Ltd's intrinsic value (as of 29 January 2026) is ₹260.61 which is 83.53% higher the current market price of ₹142.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹270 Cr. market cap, FY2025-2026 high/low of ₹239/136, reserves of ₹668 Cr, and liabilities of ₹1,005 Cr.
What is the Market Cap of Nath Bio-Genes (India) Ltd?
The Market Cap of Nath Bio-Genes (India) Ltd is 270 Cr..
What is the current Stock Price of Nath Bio-Genes (India) Ltd as on 29 January 2026?
The current stock price of Nath Bio-Genes (India) Ltd as on 29 January 2026 is ₹142.
What is the High / Low of Nath Bio-Genes (India) Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Nath Bio-Genes (India) Ltd stocks is ₹239/136.
What is the Stock P/E of Nath Bio-Genes (India) Ltd?
The Stock P/E of Nath Bio-Genes (India) Ltd is 5.73.
What is the Book Value of Nath Bio-Genes (India) Ltd?
The Book Value of Nath Bio-Genes (India) Ltd is 362.
What is the Dividend Yield of Nath Bio-Genes (India) Ltd?
The Dividend Yield of Nath Bio-Genes (India) Ltd is 1.41 %.
What is the ROCE of Nath Bio-Genes (India) Ltd?
The ROCE of Nath Bio-Genes (India) Ltd is 7.35 %.
What is the ROE of Nath Bio-Genes (India) Ltd?
The ROE of Nath Bio-Genes (India) Ltd is 6.77 %.
What is the Face Value of Nath Bio-Genes (India) Ltd?
The Face Value of Nath Bio-Genes (India) Ltd is 10.0.